Cartesian Therapeutics to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ

Core Insights - Cartesian Therapeutics, Inc. is a clinical-stage biotechnology company focused on pioneering cell therapy for autoimmune diseases [3] - The company will participate in a fireside chat at the H.C. Wainwright 3rd Annual BioConnect Investor Conference on May 20, 2025 [1] Company Overview - Cartesian Therapeutics' lead asset, Descartes-08, is in Phase 3 clinical development for generalized myasthenia gravis and Phase 2 for systemic lupus erythematosus [3] - The FDA has provided written agreement for the Phase 3 trial of Descartes-08 under the Special Protocol Assessment process [3] - The clinical pipeline also includes Descartes-15, an autologous anti-BCMA CAR-T in Phase 1 trial for multiple myeloma [3] Event Information - A live webcast of the fireside chat will be available on the company's website, along with an archived replay for a limited time [2]